A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer.

TPS5618 Background: In the US, invasive cervical cancer (CC) will affect 12,710 women/year with ~4290 deaths; global deaths from CC are ~275,000 women per yr. Though treatment options for recurrent...